Side effects of chemotherapy vs. immunotherapy
Andrea B. Apolo
Phase 1 study of anti-PD-L1 durvalumab plus gefitinib in TKI-naïve patients with EGFR-mutant NSCLC
CheckMate 153 trial: how long should nivolumab be taken for?
Immunotherapy: key messages from MASCC 2016
Predictive models of tumor response to chemotherapy and radiotherapy in NSCLC